---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006906"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:16:37.213903+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Q1 net loss $56.9M ($0.59/shr); Phase 3 SMA data on track for Q4 2024

## Summary
- Net loss $56.9M ($0.59/shr) vs $39.4M ($0.49) Q1 2023; no revenue; R&D up 45% to $43.1M.
- Cash $238M as of March 31, 2024; expected to fund operations into 2H 2025.
- Phase 3 SAPPHIRE top-line data for apitegromab in SMA on track for Q4 2024; potential commercial launch in 2025 if successful.
- Initiating Phase 2 proof-of-concept trial of apitegromab + GLP-1 RA in obesity in June 2024; data expected mid-2025.
- SRK-181 data selected for oral presentation at ASCO 2024; SRK-439 preclinical data at ADA 2024.

## SEC filing metadata
- accession: 0001558370-24-006906
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837024006906/0001558370-24-006906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837024006906/srrk-20240507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006906
- JSON: https://secwatch.observer/filing/0001558370-24-006906.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006906.txt

## Key facts
- Earnings Releases
  Scholar Rock Holding Corp reported the quarter ended March 31, 2024 results: revenue no revenue, net income net loss was $56.9 million or $0.59 per share, EPS $0.59 per share.
  - Period: the quarter ended March 31, 2024
  - Revenue: no revenue
  - Net income: net loss was $56.9 million or $0.59 per share
  - EPS: $0.59 per share
  - Result: reported results
  source text: For the quarter ended March 31, 2024, net loss was $56.9 million or $0.59 per share compared to a net loss of $39.4 million or $0.49 per share for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1727196/000155837024006906/0001558370-24-006906-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.